Treatment of Anejaculatory Orgasm (Anorgasmia)

Initial Evaluation and Reversible Causes

The American Urological Association recommends replacing, adjusting dosage, or implementing staged cessation of medications contributing to delayed ejaculation/anorgasmia, particularly SSRIs, antipsychotics, and antihypertensives, in men with anejaculatory orgasm (anorgasmia) 1
The American Urological Association suggests checking morning testosterone levels, as progressively lower serum testosterone correlates with increased symptoms consistent with delayed ejaculation and anorgasmia, and offering testosterone replacement therapy per AUA guidelines for men with biochemically low testosterone and symptoms 1
For men with anejaculatory orgasm (anorgasmia) and comorbid erectile dysfunction, the American Urological Association recommends treating the erectile dysfunction first according to AUA guidelines, as erectile dysfunction and anorgasmia share common risk factors and the chronology matters for treatment sequencing 1

Behavioral modifications, such as advising men to modify sexual positions or practices to increase arousal, represent the lowest-risk first-line approach for treating anejaculatory orgasm (anorgasmia), as adequate arousal is essential for optimal ejaculatory function through psychosexual mechanisms 1
Incorporating alternative sexual practices, scripts, and sexual enhancement devices to increase physical and psychological arousal is recommended for men with anejaculatory orgasm (anorgasmia) 1
Including sexual partners in decision-making when possible is fundamental to optimizing outcomes in ejaculatory disorders, according to the American Urological Association 2, 3

Sympathomimetic agents, such as pseudoephedrine 60-120 mg, ephedrine 15-60 mg, and midodrine 5-40 mg, may be considered on an individualized basis with appropriate counseling about weak evidence and off-label use for treating anejaculatory orgasm (anorgasmia) 1
Other agents with potential benefit, including oxytocin 24 IU intranasal/sublingual, bethanecol 20 mg daily, yohimbine 5.4 mg three times daily, cabergoline 0.25-2 mg twice weekly, and imipramine 25-75 mg daily, may be considered for treating anejaculatory orgasm (anorgasmia) 1

The American Urological Association notes that no FDA-approved treatments exist for anejaculatory orgasm (anorgasmia), and all pharmacotherapy is off-label, with patients requiring understanding of the weak evidence base and potential for known/unknown side effects 2, 1
Orgasm and ejaculation are distinct from erection, and these functions can be impaired independently, with 20% of diabetic men with erectile dysfunction experiencing orgasmic dysfunction separately, according to the American Urological Association 4
Patient and partner satisfaction is the primary target outcome, not arbitrary physiological measures, in the treatment of anejaculatory orgasm (anorgasmia) 5

History of sexual abuse, decreased emotional intimacy, and relationship conflict are associated with ejaculatory disorders, according to the American Urological Association, and require assessment and possible mental health referral 6
Depression and mood disorders significantly impact arousal levels and subsequently affect orgasmic capacity, and the American Urological Association recommends assessment and possible mental health referral 6, 7

Delayed ejaculation (anorgasmia) is defined as the condition in which a man requires prolonged or more intense sexual stimulation to achieve orgasm, resulting in personal distress. This definition is endorsed by the American Urological Association (AUA) as reported in The Journal of Urology (2022). 8

Behavioral interventions that enhance sexual arousal—such as modifying sexual positions, using sexual‑enhancement devices, and involving the partner in decision‑making—enable most men to gain better ejaculatory control and improve sexual response, demonstrating that delayed ejaculation is a treatable condition. Evidence for this therapeutic approach is provided by the AUA‑referenced findings in The Journal of Urology (2022). 8